Sanofi Linked to Takeover Bid for Ocular Therapeutix
Sanofi is reportedly preparing a renewed takeover bid for US‑based Ocular Therapeutix after its initial $16‑per‑share offer was rejected last summer. Ocular, valued at roughly $2.4 billion with shares trading around $11.28, is poised to file for approval of Axpaxli, a hydrogel‑based axitinib formulation targeting wet age‑related macular degeneration (wAMD). The company’s SOL‑1 phase‑3 trial will test Axpaxli against Regeneron‑Bayer’s blockbuster Eylea, while its existing product Dextenza generates about $15 million quarterly. Acquiring Ocular would also give Sanofi access to the Elutyx drug‑delivery platform and other ophthalmic candidates.
JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview
Novo Nordisk is revamping its business‑development approach under new CEO Mike Maziar Doustdar, emphasizing intentional M&A and licensing to accelerate its obesity and diabetes pipeline. The company recently closed a $5.2 billion acquisition of Akero Therapeutics and secured a China partnership...
Komodo Health Appoints Amit Sangani to Chief Technology Officer
Komodo Health announced Amit Sangani as its new chief technology officer, tasked with steering the AI‑native Marmot platform. Sangani arrives after an 11‑year tenure at Meta, where he led large‑scale AI systems including PyTorch and Llama, and previously co‑founded MightyText....
Former Emergent CEO Hit With Insider Trading Lawsuit
The New York Attorney General sued former Emergent BioSolutions CEO Robert Kramer for alleged insider trading, claiming he sold stock based on nonpublic knowledge of vaccine contamination. Kramer reportedly profited over $10.1 million from trades executed between November 2020 and early 2021....
Writing the Code of Life: Synthetic Human Chromosomes on the Horizon
The Wellcome‑funded Synthetic Human Genome (SynHG) project has launched a £10 million, five‑year effort to develop scalable technologies for building synthetic human chromosomes. The consortium of five UK universities aims to create the first fully synthetic human genome, tackling challenges from...
Automated Twist Bioscience NGS Library Prep Workflows Enabled on SPT’s Firefly
SPT Labtech has launched validated automated workflows for Twist Bioscience’s next‑generation sequencing (NGS) library preparation kits on its firefly® liquid handling platform. The initial offering supports the FlexPrep™ UHT kit and integrates the Twist Enzymatic Fragmentation Kit 2.0, delivering higher‑throughput,...
JPM26: Korro Bio Looks To Save Itself Despite Unenviable Position
Korro Bio’s lead RNA‑editing candidate KRRO‑110 failed its Phase I/IIa trial for alpha‑1 antitrypsin deficiency, prompting an 80% stock plunge and a one‑third staff layoff. A root‑cause analysis revealed the lipid nanoparticle delivery vehicle achieved only about 25% of the...
Mega‑Fund Returns Require Unrealistic Share of Biotech Exit Pie
The Mega-Fund Math vs Reality Below is a simple case study on fund math. People are asking if a16z can really do a 3-5x on a $15B fund. To 3x net on $15B, you need ~$45B back. Assume ~5% ownership at exit. 👉 That...
European Regulators Recommended 38 Novel Drugs in 2025, 15 Fewer than the FDA
The European Medicines Agency (EMA) recommended 104 medicines for approval in 2025, marking the second‑highest total in the past 15 years. Of those, 38 are classified as novel drugs, a figure that trails the U.S. Food and Drug Administration (FDA)...
Ocugen Shares Fall, Despite Positive Eye Disorder Trial
Ocugen reported that its phase‑2 ArMaDa trial of the gene therapy OCU410 achieved a 46% reduction in geographic atrophy lesion growth for medium and high doses, with the medium dose showing a 54% reduction. The data also revealed a 60%...
Novo Nordisk, BioMarin Make AI Moves; Bristol Myers Welcomes Neurology Exec From Eisai
Novo Nordisk and BioMarin announced strategic partnerships to integrate artificial intelligence into their drug discovery pipelines, aiming to accelerate candidate identification and reduce development costs. Novo Nordisk highlighted a collaboration with a leading AI firm to model peptide therapeutics, while...
Resistance Exercise Improves Cognitive Function in Older Adults
A meta‑analysis of 17 randomized controlled trials involving 739 older adults found that resistance exercise modestly improves overall cognitive function (SMD = 0.40). Significant gains were observed in working memory (SMD = 0.44), verbal learning (MD = 3.01), and spatial memory span (SMD = 0.63), while processing speed,...
Autonomous AI Can Spot Cognitive Decline in Medical Notes
Researchers at Mass General Brigham unveiled an autonomous, agentic AI system that scans routine clinical notes to flag early cognitive impairment. The platform, built from five specialized LLM agents, demonstrated 98% specificity and 91% sensitivity in balanced testing, though real‑world...
EDETEK Launches “Ensemble” AI Managed Services
EDETEK Inc. unveiled Ensemble, an AI‑managed service that operationalizes validated, human‑supervised artificial intelligence across the clinical development lifecycle. The offering combines best‑fit large language and multimodal models, agentic automation, and domain experts to deliver production‑grade outputs such as SAP, SDTM,...
Immune-Regulating Lipid Signals May Provide a Path to Treat Chronic Inflammation
Scientists at University College London identified epoxy‑oxylipins as natural brakes that curb chronic inflammation by limiting intermediate monocyte expansion. In a human trial, the soluble epoxide hydrolase inhibitor GSK2256294 boosted epoxy‑oxylipin levels, accelerated pain resolution and lowered monocyte counts, though...
Psychiatric Nurses’ Views on AI in Care
A recent qualitative study of Chinese psychiatric nurses reveals a nuanced stance toward artificial intelligence in mental‑health care. Nurses largely view AI as a supportive tool that can automate routine tasks and enhance decision‑making, yet they voice strong concerns about...
Plant Discovery Could Lead to New Ways of Producing Medicines
Researchers at the University of York identified a bacterial‑like gene in the plant Flueggea suffruticosa that drives production of the potent alkaloid securinine, revealing that plants can co‑opt microbial enzymes for chemical defense. This discovery shows the gene family is...
Labiotech’s 15 Biopharma Companies to Watch in 2026
Labiotech‑EU hosted a special podcast where journalists Jules Adam, Roohi Peter and Willow Shah‑Neville each highlighted five biotech firms they expect to shape 2026, creating a curated list of 15 companies. The selections span gene‑therapy, immunology, neuroscience and platform technologies, featuring names such...
Patient Perspectives on Frailty Screening in Emergencies
A qualitative study published in BMC Geriatrics explores how emergency‑department patients experience frailty screening. Researchers interviewed older adults to capture feelings ranging from anxiety about being labeled frail to relief at receiving tailored care. The findings highlight how the hectic...
The We Want Them Infected Movement Isn’t Just for COVID Anymore
The U.S. Centers for Disease Control and Prevention recently trimmed the routine childhood vaccine schedule, dropping three previously recommended immunizations—hepatitis A, hepatitis B, and rotavirus—reducing the total from 18 to 11 vaccines. The change aligns the U.S. schedule more closely with Denmark’s...
Revealing RNA Polymerase II Start Sites via csRNA-Seq
A new study introduces csRNA‑seq, a high‑resolution method that captures active RNA Polymerase II transcription start sites across the genome. The technique isolates short, capped RNAs, enabling precise mapping of promoter activity without requiring chromatin immunoprecipitation. Early validation in human...
Restoring FBP1 Boosts Erectile Function in Diabetic Mice
A recent pre‑clinical study demonstrated that restoring the enzyme fructose‑1,6‑bisphosphatase 1 (FBP1) in diabetic mice markedly improves erectile function. The researchers used a targeted gene‑therapy approach to re‑express FBP1 in penile tissue, which rescued nitric oxide signaling and vascular responsiveness. Treated...
Acute Infections May Reopen Investment Door for Anti‑Infectives
1/ The Back Door Is Open How Acute Infection Could Make Anti-Infectives Investable Again Anti-infectives never died. The business model did. Low prices. Short courses. High resistance risk. Pharma walked. Now look at Alfasigma stepping into HSV encephalitis. Small deal. Narrow indication. Big implication....
Bioinformatics Blends Code with Intuition for Insight
1/ Bioinformatics isn't just code. Intuition plays an important role too. You run the stats, but you feel when something’s wrong. That feeling is a clue. https://t.co/pV5SxvYuFL
Resolving DNA Origami Structural Integrity and Pharmacokinetics in Vivo
The study introduces PLASTIQ, a proximity‑ligation assay that quantifies intact DNA origami structures in vivo with single‑helix resolution. Using ligatable staple pairs, the method detects intact nanostructures from as little as 1 µl of blood, achieving a 0.01 fM detection limit. PLASTIQ...
JPM Week 2026 Highlights: Why It Was Fantastic
My latest Biotech Scorecard newsletter, post #JPM26 edition. JPM Week 2026 is over. It was fantastic. Here’s why https://t.co/uwgz7J4WRk
Oncology M&A: Early‑Stage Deals Still Command Higher Multiples
In #oncology #M&A higher 5-yr forward revenue multiples occur for earlier stage companies, though P3 is an exception Recently multiples have declined reflecting lower valuations, later stage acquisitions, and smaller market opportunities What are some other reasons? #learnbiotechinvesting #biotech #investing #BiotechPrometheus
Agenus Closes Strategic Immunotherapeutic Collaboration with Zydus Lifesciences
Agenus finalized a $141 million strategic collaboration with Zydus Lifesciences to accelerate development and potential commercialization of its botensilimab‑balstilimab (BOT+BAL) immunotherapy combo. The deal grants Zydus exclusive rights to develop and sell BOT and BAL in India and Sri Lanka, while...
AI-Created Sensors Pave Way for Early Cancer Detection
#AI-generated sensors open new paths for early cancer detection by Anne Trafton @MIT Learn more: https://t.co/udkbd5V4cP #MedTech #Healthcare #HealthTech #Tech #TechForGood https://t.co/0SpKlYQsVA
Approved CD19 CAR‑T Cures Lymphoma; NK Therapies Lag
Currently approved CD19 CAR-T therapies extend lymphoma patient survival for years. These treatments are basically curative. Available right now for patients. On the other hand, experimental NK cell therapies have never worked because the cells aren’t persistent. @DrPatrick acts like...
Lipid Droplets: Dynamics and Organelle Interactions Explored
Recent research uncovers how lipid droplets (LDs) dynamically interact with mitochondria, endoplasmic reticulum, and lysosomes, reshaping our understanding of intracellular lipid management. High‑resolution live‑cell imaging shows rapid LD‑organelle contact formation that regulates energy production, lipid synthesis, and autophagic turnover. The...
Gene Therapy Leads Durable Clinical Value in Five Years
Which modality has the cleanest path to durable clinical value over the next 5 years?
Quantum Tools Set to Transform Life Science, Researchers Say
Japan’s National Institutes for Quantum Science and Technology (QST) published a perspective in ACS Nano outlining how quantum tools—nanoscale biosensors, hyper‑polarized MRI, and quantum‑biology‑inspired catalysts—can shift life‑science from niche labs to routine clinical and industrial use. The roadmap highlights diamond‑based nitrogen‑vacancy...
JPM Momentum and Asia’s Hotbeds of Innovation — a BioCentury Podcast
The J.P. Morgan Healthcare Conference ignited a surge of financing, the strongest in years for biotech. In a special BioCentury This Week podcast recorded at the conference, analysts and investors examined Asia’s burgeoning biotech ecosystems. Discussions covered deal pricing in China, the...
2026 U.S. Drug Pricing Outlook: ‘MFN’ Is the Future
The article forecasts that the United States will adopt a most‑favored‑nation (MFN) drug‑pricing model, tying domestic prices to international reference benchmarks. Policymakers view MFN as a tool to curb soaring prescription costs, while industry groups warn it could compress profit...
Exploring Quinoxalinyl and Quinolinyl Compounds as ALK5 Inhibitors
Researchers have synthesized a series of quinoxalinyl and quinolinyl derivatives targeting the ALK5 kinase, a key driver of fibrotic signaling. In biochemical assays, several compounds achieved sub‑micromolar potency and demonstrated high selectivity against related TGF‑β receptors. Cellular studies showed these...
Exploring Metabolic Noise Opens New Paths to Better Biomanufacturing
Washington University researchers identified enzyme copy‑number fluctuations as the primary source of metabolic noise in engineered E. coli producing the yellow pigment betaxanthin. By combining microfluidic single‑cell tracking with a bright‑fluorescent metabolite, they observed rapid switches between high‑ and low‑production states....
New York Sues Ex-Emergent CEO over Insider Trading During Vaccine Manufacturing Struggle
New York Attorney General sued the former chief executive of Emergent BioSolutions, alleging he engaged in insider trading while the company grappled with contamination problems at its Baltimore plant that delayed AstraZeneca’s COVID‑19 vaccine production. Prosecutors claim the executive sold...
Obesity Rewires Macrophages, Triggers NLRP3 Inflammation
How does obesity lead to immune system dysregulation and chronic inflammation? Macrophage metabolism is rewired, with activation of the NLRP3 inflammasome @ScienceMagazine https://t.co/bkAUgOE1c2 https://t.co/It6YaXT1b5
Yet Another New Biotech Company Aims at Regeneration of the Atrophied Thymus
Swiss biotech TECregen announced seed financing to launch a pipeline of biologic drugs aimed at regenerating the aged thymus. The company’s “thymopoietics” are engineered growth‑factor molecules designed to rebuild thymic epithelial cells, the niche essential for T‑cell maturation. By concentrating...
Multimodal AI Promises Patient‑centric Mental Health, Needs Validation
New @ScienceMagazine A thoughtful and comprehensive review on how multimodal AI can transform mental health, with emphasis on a patient-centric approach "The successful translation of AI into clinical practice will require robust validation" https://t.co/xSACrFI0tW https://t.co/8jiV6P1vdj
How Beige Fat Works to Promote Healthy Blood Pressure in Mice
Researchers at Rockefeller University demonstrated that loss of beige fat in mice triggers hypertension. Mice engineered to lack the beige‑fat regulator PRDM16 develop perivascular fibrosis and heightened sensitivity to angiotensin II. The study identified the secreted enzyme QSOX1 as the...
Acoltremon (AR-15512)
Alcon, Aerie Pharmaceuticals, and Avizorex Pharma announced FDA approval of acoltremon (Tryptyr®), the first‑in‑class TRPM8 thermoreceptor agonist for dry eye disease. The ophthalmic solution activates corneal nerves to boost natural tear production, offering a novel mechanism compared with existing anti‑inflammatory...
Hybrid Polymer Nanocarriers Improve Pulmonary mRNA Vaccine Delivery
A research team at Ludwig Maximilian University of Munich has created hybrid polymer nanocarriers combining PLGA and PBAEs to deliver inhalable mRNA vaccines. The system penetrates airway mucus, escapes endosomes, and transfects immune cells more efficiently than existing lipid nanoparticles....
Inside Fosun Pharma's Ambition to Reach Outside of China
Shanghai‑based Fosun Pharmaceutical is accelerating its transformation from a domestic generic manufacturer into a global innovator. The group has earmarked billions of dollars for overseas R&D hubs, strategic biotech partnerships and a new $2.5 billion bond to fund its expansion. Recent...
OpenAI Invests in Sam Altman’s Brain Computer Interface Startup Merge Labs
OpenAI wrote the lead check in Merge Labs’ $250 million seed round, valuing the Sam Altman‑backed brain‑computer interface startup at $850 million. Merge Labs aims to create non‑invasive BCIs that use molecular carriers and ultrasound to communicate with neurons, positioning itself as...
Qilu Mirrors JNJ with New CD79b‑CD20 Trispecific
Qilu appears to be aping $JNJ in trispecific T-cell engagers. First BCMA x GPRC5D, now CD79b x CD20. Via @ApexOnco -> https://t.co/d4pBcl0MuF
IBRX’s Dilutive ATM Funding Fuels Pump‑and‑Dump Tactics
$IBRX Anktiva q/q sales growth slowed, cash balance decreased. How much dilutive cash did the company raise from its adjusted ATM in January? https://t.co/UTKcVOAs4x Classic: Issue lots of press releases, pump stock higher, sell stock.
Alfasigma Gains Neuro Treatment; BridgeBio Offers $550M in Notes
Alfasigma has secured worldwide rights to a parenteral formulation of adibelivir for the treatment of HSV encephalitis, an ultra‑rare neurological condition. The agreement positions Alfasigma to commercialize the therapy across major markets. Meanwhile, BridgeBio announced a $550 million senior unsecured note...
Boston Scientific to Acquire Penumbra for $14.5B
Boston Scientific announced a $14.5 billion acquisition of Penumbra, paying $374 per share in cash and stock. Penumbra’s portfolio of clot‑removal and embolization devices will broaden Boston Scientific’s reach into fast‑growing thrombectomy and vascular bleeding markets. The deal values Penumbra at...